Aer Therapeutics is committed to addressing the unmet needs of patients suffering from chronic respiratory conditions

Founded by experts in respiratory medicine and drug development, Aer Therapeutics is committed to addressing the unmet needs of patients suffering from chronic respiratory conditions. The company’s innovative approach focuses on the biochemical modification of mucus to alleviate obstruction and enhance mucus clearance from the lungs. AER−01 represents a significant advancement in the treatment of respiratory diseases characterized by mucus obstruction. This therapeutic candidate is designed to liquefy mucus plugs, which are a major contributor to impaired lung function in conditions such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma.